БЕЙТМАН Никола Франсис (GB),ДЖЕЛЛЕРТ Пол Ричард (GB),ХИЛЛ Катрин Джейн (GB)
申请号：
RU2010143906/15
公开号：
RU2010143906A
申请日:
2009.03.26
申请国别(地区):
RU
年份:
2012
代理人:
摘要：
1. The pharmaceutical composition, which includes the acid sulfate salt of (2-hydroxyethoxy) amide 6- (4-bromo-2-chlorophenylamino) -7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid and a matrix carrier, where the matrix the carrier essentially consists of one or more pharmaceutically acceptable carriers selected from the following groups:! (a) d-alpha-tocopheryl polyethylene glycol 1000 succinate； ! (b) polyglycosylated glycerides； ! (c) polyethylene glycols (PEGs)； and! (d) solid fats； ! and where the acid sulfate salt of the (2-hydroxyethoxy) amide of 6- (4-bromo-2-chlorophenylamino) -7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid is dispersed in a matrix carrier. ! 2. The pharmaceutical composition according to claim 1, where the matrix carrier essentially consists of one or more groups selected from the following groups:! A. d-alpha-tocopherylpolyethylene glycol 1000 succinate； ! b. polyglycosylated glycerides； and! from. polyethylene glycol. ! 3. The pharmaceutical composition according to claim 1 or 2, where the matrix carrier essentially consists of one or both components:! but. d-alpha-tocopheryl polyethylene glycol 1000 succinate； and! b. polyglycosylated glycerides. ! 4. The pharmaceutical composition according to claim 1, where the matrix carrier is d-alpha-tocopheryl polyethylene glycol 1000 succinate or lauroyl macrogol-32 glycerides. ! 5. The pharmaceutical composition according to claim 1, where the matrix carrier is a mixture of d-alpha-tocopheryl polyethylene glycol 1000 succinate and lauroyl macrogol-32 glycerides, and where lauroyl macrogol-32 glycerides are present in an amount that is approximately 30-55% the weight of the component of the matrix carrier of the composition. ! 6. Pharmacist1. Фармацевтическая композиция, которая включает кислую сернокислую соль (2-гидроксиэтокси)амида 6-(4-бром-2-хлорфениламино)-7-фтор-3-метил-3H-бензоимидазол-5-карбоновой кислоты и матриксный носитель, где матриксный носитель существенно состоит из
